You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 6,720,153

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,720,153

Title:	Luciferase reporter bioassay of parathyroid hormone compounds
Abstract:	This invention is directed to a bioassay for determining the functionality of parathyroid hormone compounds. More particularly, this invention is directed to a bioassay wherein the compound to be tested is added to a culture of parathyroid hormone receptor expressing cells bearing a reporter gene under the transcriptional control of multiple c-AMP responsive elements.
Inventor(s):	Labaudiniere; Richard F. (Collegeville, PA), Yu; Kin T. (Limerick, PA), Crumley; Gregg R. (Philadelphia, PA), Morse; Clarence C. (Royersford, PA)
Assignee:	Aventis Pharmaceuticals Inc. (Bridgewater, NJ)
Application Number:	09/387,176
Patent Claims:	1. A method for determining the functionality of a parathyroid hormone compound, the method comprising (a) adding the compound to a culture of parathyroid hormone receptor expressing cells bearing a reporter gene under the transcriptional control of multiple cAMP responsive elements, and then measuring the expression of the reporter gene; and (b) comparing the measured expression of step (a) with the measured expression of the reporter gene in a control culture comprising: (i) the parathyroid hormone receptor expressing cells bearing the reporter gene under the transcriptional control of multiple cAMP response elements, and a parathyroid hormone, a parathyroid hormone-related protein, a parathyroid receptor agonist, or a combination thereof, or (ii) the parathyroid hormone receptor expressing cells bearing a reporter gene under the transcriptional control of multiple cAMP responsive elements, in the absence of the parathyroid hormone compound, wherein a difference between the measured expression of step (a) and the measured expression of the control culture is indicative of the functionality of the parathyroid hormone compound, and wherein the number of cAMP responsive elements is greater than about 10. 2. The method according to claim 1, wherein the number of cAMP responsive elements is about 16. 3. The method according to claim 2, wherein the cells are mammalian cells. 4. The method according to claim 2, wherein the cells comprise a heterologous nucleic acid encoding the parathyroid hormone receptor. 5. The method according to claim 2, wherein the reporter gene encodes a protein selected from the group consisting of .beta.-galactosidase, chloramphenicol acetyltransferase, .beta.-glucuronidase, and luciferase. 6. The method according to claim 5, wherein the reporter gene encodes luciferase. 7. The method according to claim 2, wherein the parathyroid hormone receptor is human parathyroid hormone receptor.

Details for Patent 6,720,153

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015	⤷ Try a Trial	2018-09-04
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.